Grace Therapeutics, Inc.
GRCE- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001444192
In the last 90 days, Grace Therapeutics, Inc. insiders filed 4 open-market purchases and 0 sales; 33 institutions reported holding it in 13F filings for Q2 2026, worth $8.97M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Grace Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 4 filings
- 2 insiders, $301.8K in total
- Open-market sells
- 0 filings
- Insiders trading
- 2
- Net value
- +$301.8K
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Grace Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Opaleye Management Inc. | 10% Owner | 2,855,318Indirect | Sep 23, 2026 | 3 |
| Neugeboren Edward | Director | – | Sep 21, 2026 | 2 |
| Davis A Brian | Director | – | Sep 21, 2026 | 2 |
| Kavuru Vimal | Director | 1,188,076Indirect | Sep 21, 2026 | 2 |
| Kottayil George | Director | – | Sep 21, 2026 | 2 |
| Kohli Prashant | Chief Executive Officer | 121,357 | Sep 10, 2026 | 2 |
| Kumar Amresh | VP Program Management | – | Sep 1, 2026 | 1 |
| Macdonald R. Loch | Chief Medical Officer | – | Sep 1, 2026 | 1 |
| DelAversano Robert J | Principal Financial Officer | – | Sep 1, 2026 | 1 |
| D'Andrea Carrie | VP Clinical Operations | – | Apr 16, 2025 | 0 |
| Olds Donald | Director | 381 | Sep 5, 2023 | 0 |
| Derby Michael | Director | – | Jul 18, 2023 | 0 |
| Canan John | Director | – | Sep 30, 2022 | 0 |
| Lemieux Pierre | COO, Canada & CSO | – | Jun 23, 2022 | 0 |
| D'Alvise Janelle | PRESIDENT & CEO | – | Jun 23, 2022 | 0 |
| Ford Brian D. | CHIEF FINANCIAL OFFICER | – | Jun 23, 2022 | 0 |
| Haseltine William A | Director | – | Nov 16, 2021 | 0 |
| Carter Roderick Noel | Director | – | Nov 16, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 23, 2026 (view filing)6:19 PM ET | Sep 21-23 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +15.1K | $2.10 | +$31.7K | +0.5%2.86M after | 2 lots |
| Sep 10, 2026 (view filing)4:05 PM ET | Sep 8-9 | 2 days | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +15.2K | $2.09 | +$31.9K | +0.6%2.78M after | 2 lots |
| Sep 10, 2026 (view filing)7:30 AM ET | Sep 9 | 1 day | Kohli PrashantChief Executive Officer | PPurchase | +100.0K | $2.14 | +$214.0K | +468.2%121.4K after | |
| Aug 19, 2026 (view filing)7:44 AM ET | Aug 14 | 5 daysLate | Opaleye Management Inc.10% Owner | PPurchaseCommon Stock, par value $0.0001 per share | +11.6K | $2.09 | +$24.2K | +0.4%2.76M after | |
| Sep 27, 2023 (view filing)7:46 PM ET | Sep 25 | 2 days | Kavuru VimalDirector, 10% Owner | PPurchase | +676.4K | $1.85 | +$1.25M | +132.2%1.19M after | |
| Sep 27, 2023 (view filing)7:46 PM ET | Sep 25 | 2 days | Kavuru VimalDirector, 10% Owner | PPurchase | +422.7K | $0.125 | +$52.8K | –422.7K after | Derivative |
| Sep 5, 2023 (view filing) | Aug 31 | 5 days | Olds DonaldDirector | PPurchase | +381 | $2.05 | +$781.05 | New position381 after |